Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $70
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $70.
Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $70.